GlassScriptPhysician profile
Raymond Park
NPI 1497744502
$5,928.11
in general payments reported to CMS, 2019-2025
42 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $121 · 2021: $1,253 · 2022: $801 · 2023: $812 · 2024: $1,253 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,453 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,452.84 |
| Education | $145.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,025.00 | 2021-2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $908.31 | 2019-2025 | |
| Abbvie INC. | $411.45 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $324.75 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $270.49 | 2021-2024 | Austedo Xr |
| Zoll Respicardia, INC. | $268.58 | 2024-2025 | Remede System |
| Merz Pharmaceuticals, LLC | $267.27 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Celgene Corporation | $264.45 | 2022-2025 | Zeposia |
| Janssen Biotech, INC. | $258.88 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $147.33 | 2021-2022 | |
| Eisai INC. | $132.16 | 2024-2025 | |
| Axsome Therapeutics, INC. | $123.05 | 2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $121.18 | 2024 | Lumryz |
| Tg Therapeutics, INC. | $116.35 | 2023-2025 | |
| Harmony Biosciences LLC | $113.56 | 2023 | Wakix |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $110.77 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $79.71 | 2020-2023 | Rytary |
| Allergan, INC. | $73.01 | 2020-2022 | |
| Boston Scientific Corporation | $71.15 | 2024-2025 | Vercise |
| Csl Behring | $68.53 | 2024-2025 | Hizentra |
| Acorda Therapeutics, INC | $61.80 | 2022-2023 | Inbrija, Ampyra |
| Alnylam Pharmaceuticals INC. | $58.01 | 2025 | Amvuttra |
| Novo Nordisk INC | $58.00 | 2025 | |
| Emd Serono, INC. | $54.51 | 2021-2025 | |
| Pfizer INC. | $49.37 | 2024 | |
| Acadia Pharmaceuticals INC | $45.58 | 2024 | Nuplazid |
| Argenx US, INC. | $44.63 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $43.31 | 2021-2025 | Uplizna |
| Upsher-Smith Laboratories LLC | $43.02 | 2020 | |
| Neurelis, INC. | $42.86 | 2023-2024 | Valtoco |
| Lilly USA, LLC | $34.22 | 2019-2024 | Emgality, Reyvow |
| Ucb, INC. | $32.88 | 2025 | Rystiggo |
| Neurocrine Biosciences, INC. | $24.95 | 2024 | Ingrezza |
| Sanofi-Aventis U.S. LLC | $23.17 | 2020 | |
| Kedrion Biopharma, INC. | $23.05 | 2025 | Gammaked, Kedrab, Albuked |
| Takeda Pharmaceuticals U.S.A., INC. | $22.23 | 2023 | Gammagard |
| Cycle Pharmaceuticals INC | $20.53 | 2024 | Tascenso Odt |
| Genentech USA, INC. | $20.02 | 2023 | Ocrevus |
| Astrazeneca Pharmaceuticals LP | $19.97 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.50 | 2020 | |
| Lundbeck LLC | $17.23 | 2025 | Vyepti |
| Inspire Medical Systems, INC. | $15.29 | 2023 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.